3 completed, 1 recruiting. 3 Phase 1, 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 3 | Completed 2, Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow EyeGene Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old EG-MCV4, Menveo - Meningococcal Infections | Phase 2 / Phase 3 | Recruiting | EyeGene Inc. | 1123 | 2025-10-15 | 2025-12-01 |
| Study to Safety, Tolerability and Immunogenicity of EG-COVII in Healthy Adult EG-COVII - COVID-19 | Phase 1 / Phase 2 | Completed | EyeGene Inc. | 40 | 2023-11-30 | 2025-03-07 |
| Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers EG-COVID-003, EG-COVID-001, A: EG-COVID - COVID-19 Vaccine | Phase 1 / Phase 2 | Completed | EyeGene Inc. | 67 | 2022-03-22 | 2025-03-07 |
| Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-HZ in Healthy Adult Volunteers Treatment 1 (EG-HZ-001), Treatment 2 (EG-HZ-002), Treatment 3 (EG-HZ-003) - Prevention of Herpes Zoster (HZ) | Phase 1 | Completed | EyeGene Inc. | 40 | 2020-02-24 | 2021-02-08 |
Bacterial Infections (1) · COVID-19 (1) · Gram-Negative Bacterial Infections (1) · Infections (1) · Meningococcal Infections (1)
Meningococcal Vaccines (1) · Vaccines, Conjugate (1)
Australia (3) · South Korea (1)
Christina Chang, Dr. (1) · Mark Bloch, A/Prof (1)